Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix for OHSS Prevention in PCOS Women Undergoing IVF
NCT01709942Phase 3Completed
- Sponsor
- Centre for Endocrinology and Reproductive Medicine
- Start
- Nov 2012
- Primary completion
- Dec 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of degarelix in ovarian hyperstimulation syndrome (OHSS) (2 arms), sponsored by Centre for Endocrinology and Reproductive Medicine. Primary endpoints: Pregnancy Rate at 6 months and Ovarian Hyperstimulation Syndrome Rate at 6 months. Started Nov 2012; status: completed.
02
Drugs
degarelix
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on NCT01709942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01709942.